Clinical trials: Ejection Fraction
Heart Failure With Preserved Ejection Fraction (HFPEF)
Copenhagen Heart Failure With Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFpEF) has grown to become the dominant form of heart failure (HF) worldwide, in tandem with ageing of the general population and the increasing prevalence of obesity, diabetes…
- Trial name
- CPH-HFpEF (NCT06685237)
- Where
- Denmark
- Volunteers
- 5,000 people
- Sponsor
- Tor Biering-Sørensen
Heart Failure, Diastolic, Heart Failure，Congestive
PREFERS (Preserved and Reduced Ejection Fraction Epidemiological Regional Study) Stockholm Heart Failure Study
Heart failure (HF) with preserved (HFpEF) or reduced (HFrEF) ejection fraction is associated with poor prognosis and quality of life.
- Trial name
- PREFERS (NCT03671122)
- Testing
- Cardiac imaging in the PREFERS and CABG PREFERS cohorts, Biomarker analysis in the PREFERS and CABG PREFERS chorts, Cardiac biopsies in the CABG PREFERS cohort
- Where
- Sweden
- Volunteers
- 683 people
- Sponsor
- Karolinska Institutet
Chronic Heart Failure With Reduced Ejection Fraction
Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction
The purpose of this study was to collect safety and tolerability data on LCZ696 in eligible PARADIGM-HF patients who received open-label investigational drug.
- Trial name
- NCT02226120
- Testing
- LCZ696
- Where
- 394 sites in United States, Argentina and 39 more
- Volunteers
- 1,980 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure, Heart Failure With Preserved Ejection Fraction
EMPAGUM: Effects of Empagliflozin on Gut Microbiota in Heart Failure With a Preserved Ejection Fraction
Empagliflozin was recommended for patients with heart failure with reduced ejection fraction (HFrEF) in 2021 European Society of Cardiology (ESC) guidelines (Class of Recommendation Ia) and patients with heart failure with…
- Trial name
- NCT05584319
- Testing
- Empagliflozin 10 Mg
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Zhijun Sun
Diabetes Mellitus, Heart Failure
Comparison of Empagliflozin and Dapagliflozin in Patients With Heart Failure Taking Standard Treatment
Participants were enrolled and randomly divided in two groups. In group A, participants were prescribed Dapagliflozin 10 mg daily. In group B, participants were prescribed Empagliflozin 10 mg daily.
- Trial name
- NCT06915870
- Testing
- Dapagliflozin 10 mg daily, Empagliflozin 10 MG OD
- Where
- Pakistan
- Volunteers
- 108 people
- Sponsor
- Fatima Maqsood
ST Elevation Myocardial Infarction
The Relationship Between Myonectin Concentration and the Course of ST-segment Elevation Myocardial Infarction
The aim of this study is to test the potentially protective role of myonectin in patients with a first episode of ST elevation myocardial infarction (MI) treated with primary percutaneous coronary intervention (PCI).
- Trial name
- NCT05700773
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Michał Jaśkiewicz
Coronary Artery Disease, Cognitive Impairment
International Study of Comparative Health Effectiveness With Medical and Invasive Approaches-Left Ventricular Dysfunction Trial
The ISCHEMIA-HF trial will randomize participants with multivessel coronary artery disease (CAD) with ejection fraction (EF) ≤40% in a 1:2:2 fashion to guideline-directed medical therapy (GDMT):coronary artery bypass grafting…
- Conditions
- Coronary Artery Disease, Cognitive Impairment, Heart Failure
- Trial name
- ISCHEMIA-LVD (NCT06566183)
- Testing
- Guideline-directed medical therapy (GDMT), Coronary artery bypass grafting (CABG), Percutaneous coronary intervention (PCI).
- Where
- 6 sites in United States, Brazil and 4 more
- Volunteers
- 1,200 people
- Sponsor
- NYU Langone Health
Out-of-Hospital Cardiac Arrest, Extracorporeal Cardiopulmonary Resuscitation
Left Ventricular Ejection Fraction in Cardiac Arrest Survivors Treated With Extracorporeal Cardiopulmonary Resuscitation
Extra-hospital cardiac arrest is a major public health problem, with approximately 46,000 cases per year. Nearly 71% of the patients for whom resuscitation was initiated did not present a return of spontaneous circulation on…
- Trial name
- FEVGECMO (NCT06046339)
- Testing
- Collection of data from the patient's medical file
- Where
- France
- Volunteers
- 116 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
His Bundle Pacing, Heart Failure, Systolic
His-bundle Pacing vs. Right Ventricular Apical Pacing in Patients With Reduced Ejection Fraction
The study compares standard right ventricle apical pacing with so called His-bundle pacing, for patients with slightly or moderately reduced ejection fraction and atrioventricular block requiring pacemaker therapy.
- Trial name
- HIS-PrEF (NCT04529577)
- Testing
- His-bundle pacing
- Where
- 3 sites in Sweden
- Volunteers
- 40 people
- Sponsor
- Region Skane
Heart Failure
Effect of Finerenone on Myocardial Fibrosis and Cardiac Function in HFmrEF/HFpEF Patients
FINE-FOCUS study is a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of Finerenone versus placebo on myocardial fibrosis and cardiac structure/function as assessed by…
- Trial name
- FINE-FOCUS (NCT07583173)
- Testing
- Oral finerenone
- Where
- China
- Volunteers
- 104 people
- Sponsor
- China National Center for Cardiovascular Diseases
Heart Failure With Reduced Ejection Fraction (HFrEF), Diabete Type 2
Value of SGLT2 Inhibitor (Dapagliflozin) as an Added Therapy in Diabetic Patients With Heart Failure With Reduced Ejection Fraction; Randomized Controlled Clinical Trial
Type 2 diabetes mellitus (T2DM) is a well-recognized independent risk factor for heart failure (HF). Whereas the prevalence of HF in the general population is 1-4%, it reaches approximately 12% in T2DM patients.
- Conditions
- Heart Failure With Reduced Ejection Fraction (HFrEF), Diabete Type 2, Cardiomyopathies
- Trial name
- NCT04304560
- Testing
- Dapagliflozin 10 MG
- Volunteers
- 60 people
- Sponsor
- Damanhour University
Heart Failure, Sleep Apnea Syndromes
Oxygen Versus PAP for Sleep Apnea in Heart Failure
The purpose of this study is to compare three treatment modalities for central, or mixed obstructive and central, sleep apnea in patients with chronic heart failure and reduced ejection fraction.
- Trial name
- OPTIMAL-HF (NCT01807897)
- Testing
- Continuous positive airway pressure, Nocturnal supplemental oxygen, Healthy Lifestyle and Sleep Education
- Where
- 2 sites in United States
- Volunteers
- 74 people
- Sponsor
- VA Office of Research and Development
Heart Failure With Reduced Ejection Fraction (HFrEF)
Atrial Shunt for the Treatment of Heart Failure With Reduced Ejection Fraction
To evaluate the safety and effectiveness of the Atrial Shunt for the treatment of heart failure with reduced ejection fraction (HFrEF)
- Trial name
- PAST-HFrEF (NCT07820410)
- Testing
- D-shant Atrial Shunt, Guideline-Directed Medical Therapy (GDMT) for heart failure with reduced ejection fraction
- Where
- China
- Volunteers
- 208 people
- Sponsor
- Beijing Anzhen Hospital
Ventricular Dysfunction
Hemodynamic Indices Predictive of a Beneficial Response to Fluid Expansion in Case of Hemodynamic Failure After Cardiac Surgery With Altered Preoperative Ejection Fraction (LVEF≤45%)
Low Cardiac Output Syndrome occurs frequently after cardiac surgery, especially when pre-operative LVEF is altered (LVEF≤45%). The correction of hemodynamic failure requires adapted treatments: fluid expansion and/or inotropic or…
- Trial name
- ALTERVOL (NCT01673230)
- Testing
- cardiac surgery for ventricular dysfunction
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Rennes University Hospital
Heart Failure With Normal Ejection Fraction
Exercise Intolerance in Heart Failure
The investigators are studying whether metabolic abnormalities in cardiac and skeletal muscle in patients with heart failure with preserved ejection fraction (HFpEF) are associated with debilitating exercise intolerance.
- Trial name
- NCT03775577
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Heart Failure
This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms
The primary objective of the study is to evaluate the effect of empagliflozin 10 mg versus placebo on exercise ability using the 6 minute walk test in patients with chronic HF with reduced ejection fraction (LVEF ≤ 40%) Secondary…
- Trial name
- NCT03448419
- Testing
- Empagliflozin
- Where
- 109 sites in United States, Australia and 9 more
- Volunteers
- 312 people
- Sponsor
- Boehringer Ingelheim
Left Ventricular Dysfunction
Use of Adult Autologous Stem Cells in Treating People 2 to 3 Weeks After Having a Heart Attack (The Late TIME Study)
More than 1 million Americans suffer heart attacks each year. Although current treatments are able to stabilize the condition of the heart, none is able to restore heart function as it was prior to the heart attack.
- Trial name
- NCT00684060
- Testing
- Adult stem cells
- Where
- 5 sites in United States
- Volunteers
- 87 people
- Sponsor
- The University of Texas Health Science Center, Houston
Heart Failure With Preserved Ejection Fraction (HFpEF)
Characteristics, Phenotypes, and TRAITS of Heart Failure With Preserved Ejection Fraction (TRAITS-HFpEF)
Heart failure with preserved ejection fraction (HFpEF), a certain type of heart failure, occurs when the heart doesn't pump blood around the body properly. It can cause breathlessness, tiredness, and swollen feet or ankles.
- Trial name
- TRAITS-HFpEF (NCT05383287)
- Where
- United Kingdom
- Volunteers
- 1,250 people
- Sponsor
- Manchester University NHS Foundation Trust
Heart Failure With Reduced Ejection Fraction (HF-rEF)
Study of Efficacy and Safety of LCZ696 in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction
The purpose of this study was to assess the effect of LCZ696 at a target dose of 200 mg b.i.d. compared to enalapril 10 mg b.i.d., in addition to the background heart failure (HF) treatment, on delaying time to first occurrence…
- Trial name
- PARALLEL-HF (NCT02468232)
- Testing
- LCZ696, Enalapril
- Where
- 49 sites in Japan
- Volunteers
- 225 people
- Sponsor
- Novartis Pharmaceuticals
Heart Disease, Heart Failure
Non-interventional Study on Guideline Directed Medical Therapy for Patients With Heart Failure (HF) in Germany
Heart failure (HF) is a global public health issue that affects more than 63 million people worldwide. The clinical and economic burden of HF on health care systems is substantial.
- Conditions
- Heart Disease, Heart Failure, Cardiovascular Disease, Heart Failure, Systolic
- Trial name
- PHRASE-HF (NCT06675552)
- Where
- 6 sites in Germany
- Volunteers
- 338 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.